"The problem would not be nearly so severe if the drugs' government-granted monopolies were shorter. Once generic versions are allowed to compete, a medicine's price often drops by almost half, sometimes more than 85 percent, if enough competitors jump into the market. Yet the government tends to do the opposite, the Brigham and Women's researchers found, by extending market exclusivity via additional patents for trivial alterations -- a new coating on a pill, for example. This is nonsensical: Unless a drug is transformed in a way that affects its therapeutic value, it should not qualify for an extended patent. Drug makers often stretch their own market exclusivity by paying generics companies to delay introducing competitive medicines. The government, which is protecting these companies' monopoly rights, should demand an end to this tactic."
Wednesday, November 2, 2016
The Real Reason Drugs Cost Too Much; Bloomberg View, 8/23/16
Editorial Board, Bloomberg View; The Real Reason Drugs Cost Too Much: